Selection of two regional centers for the development and production of mRNA vaccines in Latin America

27/09/2021

On 21 September 2021, PAHO announced the selection of two regional centers for the development and production of mRNA vaccines in Latin America, in a bid to tackle COVID-19 and future infectious-disease challenges. The selection is the result of an April 2021 WHO call for expressions of interest by manufacturers and research institutions. 

The selected centers are the following: Brazil's Bio-Manguinhos Institute of Technology on Immunobiologicals, at the Oswaldo Cruz Foundation (FIOCRUZ), has a long tradition in vaccine manufacturing and has made promising advances in the development of an innovative mRNA vaccine against COVID-19; and the private-sector biopharmaceutical company Sinergium Biotech, in Argentina, will be partnering with pharmaceutical mAbxience, which belongs to the same group, to develop and manufacture active vaccine ingredients. The two companies have extensive experience in the area.  

Source: https://www.paho.org/en/news/21-9-2021-paho-selects-centers-argentina-brazil-develop-covid-19-mrnavaccines

  • Share: